Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Dev Regulatory News (FDEV)

Share Price Information for Frontier Dev (FDEV)

Share Price is delayed by 15 minutes
Get Live Data
461.50    5.00 (1.10%)
Bid:
455.50
Ask:
460.00
Spread: 4.50 (0.988%)
Market Cap: £160.29m
FDEV Live PriceLast checked at - London Stock Exchange

Intraday Frontier Dev Share Chart

Trading Update

22 Apr 2015 07:00

RNS Number : 9117K
Frontier Developments PLC
22 April 2015
 



22 April 2015

Frontier Developments plc

Trading Update

Frontier Developments plc (AIM: FDEV, "Frontier", the "Group"), a leading developer of video games, announces the following trading update.

Elite: Dangerous 

The Board continues to be pleased with the progress of Elite: Dangerous to date. Total unit sales now exceed 500,000. The retail price remains £40 (US$60, €50).

The Group continues to add new platforms and distribution channels to further expand the audience. In addition to the forthcoming availability on Apple's Mac computers next month, and Microsoft's Xbox One games console later this year, Elite: Dangerous was recently made available on the Steam digital distribution service, entering at number 1 in their sales charts just before Easter.

Cash Position

The Group's balance sheet remains strong and, at 31 March 2015, the Group had net cash of approximately £11.4 million. This places the Group in a good financial position to support its continuing investment plans going forwards. As a result, the Group has reviewed its cash resource requirements for the next 12 months and decided to lower its revolving credit facility with Barclays Bank plc from £3m to £1m. This facility expires in May 2016.

David Braben, Chief Executive of Frontier Developments, said:

"The team did a great job in delivering the full public release of Elite: Dangerous and its supporting technology as planned, driving our transition to the next stage. We are and will continue to support it going forwards and that has helped build a great community around the game, setting us up well for future expansion. We, as a Board, are hopeful that sales will continue to track higher than we expected in the January Trading Update, leading to Group revenues of over £22 million by the end of the current financial year ending 31 May 2015."

Enquiries:

Frontier Developments

+44 (0)1223 394 300

David Braben, CEO

David Walsh, COO

Neil Armstrong, CFO

 

 

 

 

Canaccord Genuity

+44 (0) 207 523 8000

Simon Bridges/Cameron Duncan

 

 

 

 

Finncap

+44 (0) 207 220 0506

Charlotte Stranner

 

 

 

 

Tulchan Communications

+44 (0) 207 353 4200

James Macey White

 

 

 

About Frontier Developments plc 

Frontier Developments plc, listed on the AIM stock market (AIM: FDEV), is a leading independent game developer founded in 1994 by David Braben, co-author of the seminal 'Elite' game. Based in Cambridge, Frontier uses its proprietary 'Cobra' game development technology to create innovative games across videogame consoles, computers, smartphones and tablets.

The studio released Zoo Tycoon as a launch title for Microsoft's Xbox One console in 2013 and Tales from Deep Space for Amazon in 2014. It continues to work on ScreamRide for Microsoft and other unannounced titles in addition to expansion of Elite: Dangerous.

www.frontier.co.uk

Important Note

The information contained in this announcement about the sales of Elite: Dangerous relates solely to this game and does not constitute a profit estimate or profit forecast in respect of the Group or any guidance as to the likely profits of the Group. The scenarios contained in the announcement have been prepared by the directors based on their own industry knowledge and analysis and there are a number of factors which could or may cause the actual sales of the game and revenue generated from such sales to differ materially from those expressed or implied by such scenarios.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTIBMATMBATBIA
Date   Source Headline
19th Mar 20267:00 amRNSTransaction in Own Shares
18th Mar 20267:00 amRNSDirector/PDMR Shareholding
18th Mar 20267:00 amRNSTransaction in Own Shares
17th Mar 20267:00 amRNSDirector/PDMR Shareholding
17th Mar 20267:00 amRNSDirector/PDMR Shareholding
17th Mar 20267:00 amRNSTransaction in Own Shares
17th Mar 20267:00 amRNSTransaction in Own Shares
16th Mar 20267:00 amRNSDirector/PDMR Shareholding
16th Mar 20267:00 amRNSDirector/PDMR Shareholding
16th Mar 20267:00 amRNSTransaction in Own Shares
16th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 20267:00 amRNSDirector/PDMR Shareholding
13th Mar 20267:00 amRNSDirector/PDMR Shareholding
13th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 20267:00 amRNSTransaction in Own Shares
12th Mar 20267:00 amRNSDirector/PDMR Shareholding
12th Mar 20267:00 amRNSTransaction in Own Shares
11th Mar 20267:00 amRNSDirector/PDMR Shareholding
11th Mar 20267:00 amRNSDirector/PDMR Shareholding
11th Mar 20267:00 amRNSTransaction in Own Shares
11th Mar 20267:00 amRNSTransaction in Own Shares
10th Mar 20267:00 amRNSDirector/PDMR Shareholding
10th Mar 20267:00 amRNSTransaction in Own Shares
10th Mar 20267:00 amRNSTransaction in Own Shares
9th Mar 20267:00 amRNSDirector/PDMR Shareholding
9th Mar 20267:00 amRNSTransaction in Own Shares
6th Mar 20267:00 amRNSTransaction in Own Shares
5th Mar 20267:00 amRNSDirector/PDMR Shareholding
5th Mar 20267:00 amRNSTransaction in Own Shares
4th Mar 20267:00 amRNSDirector/PDMR Shareholding
4th Mar 20267:00 amRNSTransaction in Own Shares
3rd Mar 20267:00 amRNSDirector/PDMR Shareholding
3rd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20267:00 amRNSDirector/PDMR Shareholding
2nd Mar 20267:00 amRNSTransaction in Own Shares
27th Feb 20267:00 amRNSDirector/PDMR Shareholding
27th Feb 20267:00 amRNSTransaction in Own Shares
26th Feb 20267:00 amRNSLaunch of on-market Share Buyback Programme
26th Feb 20267:00 amRNSBlock Listing Return
11th Feb 202610:45 amRNSOption Grants / PDMR Dealings
27th Jan 20263:43 pmRNSHolding(s) in Company
14th Jan 20267:00 amRNSExcellent H1 Results & full year outlook upgraded
2nd Jan 20267:00 amRNSAppointment of Chief Executive Officer
2nd Jan 20267:00 amRNSAppointment of Chief Executive Officer
16th Dec 20257:00 amRNSCEO TRANSITION
14th Nov 20251:37 pmRNSDirector/PDMR Shareholding
6th Nov 20257:00 amRNSA STRONG LAUNCH FOR JWE3 & A SEQUEL FOR PLANET ZOO
5th Nov 20258:57 amRNSHolding(s) in Company
29th Oct 202510:48 amRNSResult of AGM
21st Oct 20253:00 pmRNS-RJURASSIC WORLD EVOLUTION 3 IS OUT NOW!

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.